Guselkumab significantly improved joint symptoms, physical function, psoriasis, enthesitis, dactylitis and quality of life in patients with active psoriatic arthritis, researchers report.
Myeloablative autologous hematopoietic stem cell transplantation is a superior treatment in the long term as compared to cyclophosphamide for severe scleroderma, research shows.
The calcineurin inhibitor voclosporin has shown superior complete remission rates among lupus nephritis patients taking 23.7 mg (considered a low dose) of the drug, twice daily.
Denosumab significantly increased spine and hip bone mineral density as compared to risedronate in osteoporosis patients treated with glucocorticoids.
ACR 2016: Denosumab increases spine and hip bone mineral density in glucocorticoid-induced osteoporosis.
Improving care for high-need, high-cost patients is an imperative for patients and the healthcare system. Programs are in development, NEJM perspective reports.